Advice

Recommended for restricted use within NHS Scotland.

RECOMMENDATION.

Valganciclovir has been approved for prevention of cytomegalovirus (CMV) disease in CMVnegative patients who have received a solid organ transplanted from a CMV-positive donor.

It can be given once daily compared with three times daily for existing treatment, thereby improving compliance and convenience.

Use of Valganciclovir should only be initiated by physicians in transplantation or infectious disease units.

Download detailed advice18KB (PDF)

Download

Medicine details

Medicine name:
Valganciclovir (Valcyte)
SMC ID:
62/03
Indication:
prevention of cytomegalovirus (CMV) disease in CMV-negative patients who have received a solid organ transplanted from a CMV-positive donor
Pharmaceutical company
Roche
BNF chapter
Infections
Submission type
Abbreviated
Status
Restricted
Date advice published
08 September 2003